Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Ardelyx, Inc. (ARDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.44, with a market capitalisation of $908.82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.36 to $8.40. This page covers its latest market performance, valuation, price trends and company information.
$908.82M | |
$3.44 | |
$35.48 | |
$0.49 | |
$3.40 | |
5.26K | |
4.38M | |
-- | |
$8.40 | |
$3.36 | |
-- | |
-- |
Ardelyx, Inc. (ARDX) is trading at $3.44 in pre-market trading as of 2026-09-16 12:12:00, up 1.09% ($0.04) from the previous close of $3.40
Pre-market trading shows how investors are pricing ARDX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Ardelyx, Inc. (ARDX) moved from $3.78 to $3.44, representing a decline of 9.07% ($0.34).
The stock traded between $3.36 and $3.92 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 4.23 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.5%
ARDX is currently trading at $3.44, placing it 1.5% of the way from its 52-week low of $3.36 to its 52-week high of $8.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 489 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ardelyx, Inc. (ARDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.